Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: a retrospective analysis.

Qin T, Yuan ZY, Peng RJ, Zeng YD, Shi YX, Teng XY, Liu DG, Bai B, Wang SS.

Curr Oncol. 2013 Aug;20(4):196-204. doi: 10.3747/co.20.1231.

2.

A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.

Gu R, Jia W, Zeng Y, Rao N, Hu Y, Li S, Wu J, Jin L, Chen L, Long M, Chen K, Chen L, Xiao Q, Wu M, Song E, Su F.

BMC Cancer. 2012 May 1;12:161. doi: 10.1186/1471-2407-12-161.

3.

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.

Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K, Edwards MJ.

Cancer. 2010 May 15;116(10):2307-15. doi: 10.1002/cncr.24940.

4.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
5.

Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.

Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E, Joensuu H.

J Clin Oncol. 2000 Oct 15;18(20):3487-94.

PMID:
11032589
6.

Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.

Love RR, Van Dinh N, Quy TT, Linh ND, Tung ND, Shen TZ, Hade EM, Young GS, Jarjoura D.

J Clin Oncol. 2008 Jan 10;26(2):253-7. Epub 2007 Dec 17.

PMID:
18086800
7.

Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer.

Kimura M, Tominaga T, Kimijima I, Takatsuka Y, Takashima S, Nomura Y, Kasumi F, Yamaguchi A, Masuda N, Noguchi S, Eshima N.

Breast Cancer. 2014 May;21(3):275-83. doi: 10.1007/s12282-012-0394-6. Epub 2012 Sep 12.

PMID:
22968626
8.

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.

International Breast Cancer Study Group, Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, Simoncini E, Castiglione-Gertsch M, Coates AS, Goldhirsch A.

Ann Oncol. 2004 Dec;15(12):1749-59.

PMID:
15550579
9.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators.

Lancet Oncol. 2010 Dec;11(12):1135-41. doi: 10.1016/S1470-2045(10)70257-6. Epub 2010 Nov 17.

PMID:
21087898
10.

Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials.

Zhou WB, Ding Q, Chen L, Liu XA, Wang S.

Breast Cancer Res Treat. 2011 Aug;128(3):625-31. doi: 10.1007/s10549-011-1556-5. Epub 2011 May 7. Review.

PMID:
21553116
11.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M.

Lancet Oncol. 2008 Jan;9(1):45-53.

PMID:
18083636
12.

Toremifene versus tamoxifen for advanced breast cancer.

Mao C, Yang ZY, He BF, Liu S, Zhou JH, Luo RC, Chen Q, Tang JL.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008926. doi: 10.1002/14651858.CD008926.pub2. Review.

PMID:
22786516
13.

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.

Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Hacking A, Cortes-Funes H, Forbes J, et al.

Ann Oncol. 1994 Oct;5(8):717-24.

PMID:
7826904
14.

Toremifene in the treatment of breast cancer.

Mustonen MV, Pyrhönen S, Kellokumpu-Lehtinen PL.

World J Clin Oncol. 2014 Aug 10;5(3):393-405. doi: 10.5306/wjco.v5.i3.393. Review.

15.

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.

J Clin Oncol. 2006 Mar 20;24(9):1332-41. Epub 2006 Feb 27.

PMID:
16505417
16.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.

17.

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Noguchi S.

Lancet Oncol. 2012 Apr;13(4):345-52. doi: 10.1016/S1470-2045(11)70373-4. Epub 2012 Jan 20.

PMID:
22265697
18.
19.

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. doi: 10.1007/s00432-008-0414-2. Epub 2008 May 17.

PMID:
18488249
20.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004562. doi: 10.1002/14651858.CD004562.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004562.

PMID:
18843661

Supplemental Content

Support Center